The University of California, San Francisco cancer of the prostate risk assessment score: A straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy

被引:623
作者
Cooperberg, MR
Pasta, DJ
Elkin, EP
Litwin, MS
Latini, DM
DuChane, J
Carroll, PR
机构
[1] Univ Calif San Francisco, Mt Zion Canc Ctr, San Francisco, CA 94115 USA
[2] Univ Calif Los Angeles, Los Angeles, CA USA
[3] TAP Pharmaceut Prod Inc, Lake Forest, IL USA
关键词
prostatic neoplasms; risk factors; prognosis; prostate-specific antigen;
D O I
10.1097/01.ju.0000158155.33890.e7
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Multivariate prognostic instruments aim to predict risk of recurrence among patients with localized prostate cancer. We devised a novel risk assessment tool which would be a strong predictor of outcome across various levels of risk, and which could be easily applied and intuitively understood. Materials and Methods: We studied 1,439 men diagnosed between 1992 and 2001 who had undergone radical prostatectomy and were followed in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) database, a longitudinal, community based disease registry of patients with prostate cancer. Disease recurrence was defined as prostate specific antigen (PSA) 0.2 ng/ml or greater on 2 consecutive occasions following prostatectomy or a second cancer treatment more than 6 months after surgery. The University of California, San Francisco-Cancer of the Prostate Risk Assessment (UCSF-CAPRA) score was developed using preoperative PSA, Gleason score, clinical T stage, biopsy results and age. The index was developed and validated using Cox proportional hazards and life table analyses. Results: A total of 210 patients (15%) had recurrence, 145 by PSA criteria and 65 by second treatment. Based on the results of the Cox analysis, points were assigned based on PSA (0 to 4 points), Gleason score (0 to 3), T stage (0 to 1), age (0 to 1) and percent of biopsy positive cores (0 to 1). The UCSF-CAPRA score range is 0 to 10, with roughly double the risk of recurrence for each 2-point increase in score. Recurrence-free survival at 5 years ranged from 85% for a UCSF-CAPRA score of 0 to 1 (95% CI 73%-92%) to 8% for a score of 7 to 10 (95% Cl 0%-28%). The concordance index for the UCSF-CAPRA score was 0.66. Conclusions: The UCSF-CAPRA score is a straightforward yet powerful preoperative risk assessment tool. It must be externally validated in future studies.
引用
收藏
页码:1938 / 1942
页数:5
相关论文
共 20 条
[1]   Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer [J].
Albertsen, PC ;
Hanley, JA ;
Gleason, DF ;
Barry, MJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11) :975-980
[2]   The contemporary management of prostate cancer in the United States: Lessons from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), a national disease registry [J].
Cooperberg, MR ;
Broering, JM ;
Litwin, MS ;
Lubeck, DP ;
Mehta, SS ;
Henning, JM ;
Carroll, PR .
JOURNAL OF UROLOGY, 2004, 171 (04) :1393-1401
[3]   Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer [J].
D'Amico, AV ;
Whittington, R ;
Malkowicz, SB ;
Schultz, D ;
Blank, K ;
Broderick, GA ;
Tomaszewski, JE ;
Renshaw, AA ;
Kaplan, I ;
Beard, CJ ;
Wein, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11) :969-974
[4]   Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer [J].
D'Amico, AV ;
Whittington, R ;
Malkowicz, SB ;
Schultz, D ;
Fondurulia, J ;
Chen, MH ;
Tomaszewski, JE ;
Renshaw, AA ;
Wein, A ;
Richie, JP .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (06) :1164-1172
[5]   Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: Results from the search database [J].
Freedland, SJ ;
Aronson, WJ ;
Csathy, GS ;
Kane, CJ ;
Amling, CL ;
Presti, JC ;
Dorey, F ;
Terris, MK .
UROLOGY, 2003, 61 (04) :742-747
[6]   Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score [J].
Freedland, SJ ;
Csathy, GS ;
Dorey, F ;
Aronson, WJ .
JOURNAL OF UROLOGY, 2002, 167 (02) :516-520
[7]   Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer [J].
Graefen, M ;
Ohori, M ;
Karakiewicz, PI ;
Cagiannos, I ;
Hammerer, PG ;
Haese, A ;
Erbersdobler, A ;
Henke, RP ;
Huland, H ;
Wheeler, TM ;
Slawin, K ;
Scardino, PT ;
Kattan, MW .
JOURNAL OF UROLOGY, 2004, 171 (01) :200-203
[8]   Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: Results from cancer of the prostate strategic urological research endeavor (CaPSURE) [J].
Greene, KL ;
Meng, MV ;
Elkin, EP ;
Cooperberg, MR ;
Pasta, DJ ;
Kattan, MW ;
Wallace, K ;
Carroll, WR .
JOURNAL OF UROLOGY, 2004, 171 (06) :2255-2259
[9]   Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: Results from CaPSURE [J].
Grossfeld, GD ;
Latini, DM ;
Lubeck, DP ;
Broering, JM ;
Li, YP ;
Mehta, SS ;
Carroll, PR .
UROLOGY, 2002, 59 (04) :560-565
[10]   A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer [J].
Holmberg, L ;
Bill-Axelson, A ;
Helgesen, F ;
Salo, JO ;
Folmerz, P ;
Häggman, M ;
Andersson, S ;
Spångberg, A ;
Busch, C ;
Nordling, S ;
Palmgren, J ;
Adami, HO ;
Johansson, J ;
Norlén, BJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (11) :781-789